NANCY AGRAWAL, PhD
IQ Translational and ADME Sciences Leadership Group (TALG) Chair (2018-2020)
IQ TALG Member (2013-Present)
Vice President, Pharmacokinetics, Pharmacodynamics, Drug Metabolism (PPDM), Merck & Co., Inc. (Ret.)
PhD, Chemical Engineering, University of Michigan
DESCRIBE YOUR INVOLVEMENT IN THE IQ CONSORTIUM.
I began my involvement in IQ as a member of a human metabolism best practices survey working group under the Drug Metabolism Leadership Group (now Translational and ADME Sciences Leadership Group (TALG)). I was later appointed to represent Merck on the TALG, and ultimately served two-year terms as Vice Chair and Chair. I am now serving as past chair for one year.
IS THERE A TECHNOLOGY SPECIFIC TO IQ THAT SHAPED THE CONSORTIUM'S GROWTH AND SUCCESS?
In my opinion, it would be the ability to share data in a precompetitive manner via the data sharing framework developed by IQ. This framework enables IQ member companies to address scientific questions that otherwise wouldn’t be easily addressed with data from an individual pharma organization.
WHAT BENEFITS HAVE YOU, YOUR COMPANY AND COLLEAGUES ENJOYED AS A RESULT OF IQ ENGAGEMENT?
The consortium approach allows my company, and me personally, to tackle scientific problems that cannot be addressed by a single company. This unique environment also allows members to collaborate to identify and share best practices on a variety of scientific topics.
WHAT WOULD YOU SAY TO THOSE JUST FINDING OUT ABOUT IQ?
The IQ Consortium provides significant opportunities for professional development, and leadership and networking opportunities. Jump in and get engaged—it’s a great experience. Volunteering to serve on a working group is a great way to get started.